Private Advisor Group LLC Raises Holdings in Kenvue Inc. (NYSE:KVUE)

Private Advisor Group LLC boosted its stake in Kenvue Inc. (NYSE:KVUE) by 34.1% during the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 50,076 shares of the company’s stock after buying an additional 12,729 shares during the quarter. Private Advisor Group LLC’s holdings in Kenvue were worth $1,069,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Grove Bank & Trust raised its holdings in shares of Kenvue by 438.4% in the fourth quarter. Grove Bank & Trust now owns 1,163 shares of the company’s stock worth $25,000 after acquiring an additional 947 shares during the last quarter. Geneos Wealth Management Inc. purchased a new stake in Kenvue during the 4th quarter worth about $29,000. Ashton Thomas Securities LLC acquired a new position in Kenvue in the 3rd quarter valued at about $35,000. Fortitude Family Office LLC lifted its holdings in Kenvue by 106.6% in the 4th quarter. Fortitude Family Office LLC now owns 1,506 shares of the company’s stock valued at $32,000 after purchasing an additional 777 shares in the last quarter. Finally, Versant Capital Management Inc boosted its stake in shares of Kenvue by 300.8% during the 4th quarter. Versant Capital Management Inc now owns 1,920 shares of the company’s stock worth $41,000 after purchasing an additional 1,441 shares during the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Kenvue Price Performance

Kenvue stock opened at $23.58 on Friday. The firm has a fifty day moving average of $21.46 and a 200-day moving average of $22.26. Kenvue Inc. has a 52-week low of $17.67 and a 52-week high of $24.46. The company has a quick ratio of 0.69, a current ratio of 1.00 and a debt-to-equity ratio of 0.66. The firm has a market capitalization of $45.07 billion, a P/E ratio of 44.49, a PEG ratio of 2.62 and a beta of 1.45.

Kenvue (NYSE:KVUE) last announced its quarterly earnings results on Thursday, February 6th. The company reported $0.26 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. As a group, analysts predict that Kenvue Inc. will post 1.14 EPS for the current year.

Kenvue Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Wednesday, February 26th. Investors of record on Wednesday, February 12th were given a dividend of $0.205 per share. This represents a $0.82 annualized dividend and a yield of 3.48%. The ex-dividend date was Wednesday, February 12th. Kenvue’s dividend payout ratio (DPR) is presently 154.72%.

Wall Street Analysts Forecast Growth

KVUE has been the subject of a number of analyst reports. Royal Bank of Canada reissued a “sector perform” rating and issued a $24.00 price objective on shares of Kenvue in a research report on Monday, February 3rd. Deutsche Bank Aktiengesellschaft lowered Kenvue from a “buy” rating to a “hold” rating and reduced their price target for the stock from $25.00 to $24.00 in a research note on Thursday, December 12th. UBS Group lowered their price objective on Kenvue from $23.00 to $21.00 and set a “neutral” rating for the company in a research report on Friday, February 7th. Barclays decreased their price target on Kenvue from $23.00 to $21.00 and set an “equal weight” rating on the stock in a research note on Friday, January 17th. Finally, Canaccord Genuity Group dropped their price objective on shares of Kenvue from $27.00 to $24.00 and set a “buy” rating for the company in a research note on Friday, February 7th. One research analyst has rated the stock with a sell rating, eight have given a hold rating and five have given a buy rating to the company. According to MarketBeat, Kenvue presently has an average rating of “Hold” and an average price target of $23.08.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.